Medivir partner Janssen has started patient enrolment in a Phase II trial (IMPACT) of the NS3/4A protease inhibitor simeprevir to treat patients with hepatitis C genotype 1 and 4 infection and decompensated liver disease.

The open label IMPACT trial is designed to evaluate the efficacy, safety and pharmacokinetics of simeprevir administered once daily in combination with Gilead’s nucleotide inhibitor sofosbuvir and Bristol-Myers Squibb’s (BMS) NS5A replication complex inhibitor daclatasvir in treatment-naïve and treatment-experienced patients.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

During the trial, patients will be given a once-daily combination of simeprevir 150mg, sofosbuvir 400mg and daclatasvir 60mg, for 12 weeks.

The trial’s primary efficacy endpoint is the proportion of patients achieving sustained virologic response 12 weeks after the end of treatment (SVR12).

"The trial’s primary efficacy endpoint is the proportion of patients achieving sustained virologic response 12 weeks after the end of treatment (SVR12)."

The company said the IMPACT trial represents the first Phase II study concerning the combination of simeprevir, sofosbuvir and daclatasvir in a regimen without pegylated interferon and ribavirin.

See Also:

Developed jointly by Janssen R&D Ireland and Medivir, simeprevir is a potential treatment for chronic hepatitis C infection as a part of a combination antiviral treatment regimen.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Janssen is responsible for the global clinical development of simeprevir and has exclusive, worldwide marketing rights, except in the Nordic countries. Medivir retains marketing rights for the drug in these countries under the marketing authorisation held by Janssen-Cilag International.

Simeprevir was approved earlier this year to treat chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis.

The drug was approved in Japan in September 2013 and in both Canada and the US in November 2013. It was approved in Russia in March, and in Mexico and Australia in July.